Gossamer Bio, Inc.
GOSS
$2.00
-$0.04-1.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 124.59M | 114.70M | 105.32M | 95.84M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 124.59M | 114.70M | 105.32M | 95.84M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 124.59M | 114.70M | 105.32M | 95.84M | -- |
| SG&A Expenses | 35.22M | 36.13M | 35.80M | 36.58M | 37.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 179.36M | 174.62M | 168.14M | 165.23M | 167.76M |
| Operating Income | -54.77M | -59.92M | -62.82M | -69.39M | -167.76M |
| Income Before Tax | -50.35M | -55.64M | -68.34M | -76.42M | -172.58M |
| Income Tax Expenses | 893.00K | 893.00K | 3.30M | 4.44M | -- |
| Earnings from Continuing Operations | -51.24 | -56.53 | -71.65 | -80.85 | -172.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.24M | -56.53M | -71.65M | -80.85M | -172.58M |
| EBIT | -54.77M | -59.92M | -62.82M | -69.39M | -167.76M |
| EBITDA | -54.19M | -59.09M | -61.80M | -68.20M | -166.36M |
| EPS Basic | -0.37 | -0.40 | -0.32 | -0.39 | -1.05 |
| Normalized Basic EPS | -0.31 | -0.32 | -0.19 | -0.23 | -0.66 |
| EPS Diluted | -0.37 | -0.40 | -0.32 | -0.39 | -1.06 |
| Normalized Diluted EPS | -0.32 | -0.33 | -0.20 | -0.24 | -0.66 |
| Average Basic Shares Outstanding | 905.99M | 904.91M | 903.71M | 870.25M | 739.47M |
| Average Diluted Shares Outstanding | 918.31M | 917.23M | 916.03M | 882.57M | 739.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |